Yao Ding
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Yao Ding has a total of 43 co-authors. Here are the top co-authors by number of shared publications:
- Rolin L. Wade
IQVIA, Plymouth Meeting, PA USA
2 shared publications - Anne Beaubrun
Cepheid
1 shared publication Annette Okai
Multiple Sclerosis Treatment Center of Dallas, Dallas, TX, USA
1 shared publication- Daana Bajnauth
Georgetown University, Washington, DC, USA
1 shared publication - Di Wu
Department of Developmental and Regenerative Biology, iORGANtech Limited Company (Suzhou), Suzhou, 215000, China; Tianjin Key Laboratory of Early Druggability Evaluation of Innovative Drugs and Tianjin Key Laboratory of Molecular Drug Research, Tianjin International Joint Academy of Biomedicine, Tianjin, 300457, China; Department of Central Laboratory, Shenzhen Hospital, Beijing University of Chinese Medicine, Guangdong, 518000, China
1 shared publication Dionne M. Hines
Health Economics and Outcomes Research, IQVIA Inc, Plymouth Meeting, PA, USA
1 shared publication
Latest Publications
- 25 June 2022
- Published by Elsevier in Value in Health
- Vol. 25 (7) , S554
PCR70 Insulin Adherence in Individuals with Diabetes and Newly-Initiated Insulin in the U.S.
- 25 June 2022
- Published by Elsevier in Value in Health
- Vol. 25 (7) , S554
PCR70 Insulin Adherence in Individuals with Diabetes and Newly-Initiated Insulin in the U.S.
- Open Access
- 2 May 2022
- Published by Elsevier in Public Health
- Vol. 207, 127-128
COVID-19 and global mental health service delivery and financing
- 2 May 2022
- Published by Elsevier in Public Health
- Vol. 207, 127-128
Open AccessCOVID-19 and global mental health service delivery and financing
- Open Access
- 18 December 2020
- Published by Taylor & Francis in Journal of Medical Economics
- Vol. 24 (1) , 46-53
Identifying disability level in multiple sclerosis patients in a U.S.-based health plan claims database
In clinical trials, disability progression in multiple sclerosis (MS) is measured by the Kurtzke Expanded Disability Status (EDSS) score, which is not captured in routine clinical care in the U.S. ...
- 18 December 2020
- Published by Taylor & Francis in Journal of Medical Economics
- Vol. 24 (1) , 46-53
Open AccessIdentifying disability level in multiple sclerosis patients in a U.S.-based health plan claims database
In clinical trials, disability progression in multiple sclerosis (MS) is measured by the Kurtzke Expanded Disability Status (EDSS) score, which is not captured in routine clinical care in the U.S. ...
- Open Access
- 1 February 2020
- Published by Wolters Kluwer Health in Medicine
- Vol. 99 (9) , e19314
Application of computed tomography, positron emission tomography-computed tomography, magnetic resonance imaging, endobronchial ultrasound, and mediastinoscopy in the diagnosis of mediastinal lymph node staging of non-small-cell lung cancer
Background: Ruling out distant metastases, non-small cell lung cancer (NSCLC)treatment depends on the results of mediastinal node staging (N staging). Several diagnostic methods play central roles in mediastinal N staging. This study is intended to evaluate the existing diagnostic methods and report quality, and to search for the best method for staging mediastinal lymph nodes. Methods: We searched PubMed, Embase, and the Cochrane Library to identify relevant studies, including randomized controlled trials and retrospective studies. These studies report the application of computed tomography, positron emission tomography-computed tomography, magnetic resonance imaging, endobronchial ultrasound, and mediastinoscopy in the diagnosis of mediastinal lymph node staging of NSCLC. The quality of the literature was assessed using the Quality Assessment of Diagnostic Accuracy Study 2. The true positive, false positive, true negative, and false negative of each study was extracted. The corresponding sensitivity, specificity, and other indicators were calculated and the Summary Receiver Operating curve was established. Then, head-to-head and indirect comparison meta-analyses will be conducted. Results: The results of this study will be published in a peer-reviewed journal. Conclusion: This study will provide basis for mediastinal lymph node staging of non-small cell lung cancer. PROSPERO registration number: CRD42019145667
- 1 February 2020
- Published by Wolters Kluwer Health in Medicine
- Vol. 99 (9) , e19314
Open AccessApplication of computed tomography, positron emission tomography-computed tomography, magnetic resonance imaging, endobronchial ultrasound, and mediastinoscopy in the diagnosis of mediastinal lymph node staging of non-small-cell lung cancer
Background: Ruling out distant metastases, non-small cell lung cancer (NSCLC)treatment depends on the results of mediastinal node staging (N staging). Several diagnostic methods play central roles in mediastinal N staging. This study is intended to evaluate the existing diagnostic methods and report quality, and to search for the best method for staging mediastinal lymph nodes. Methods: We searched PubMed, Embase, and the Cochrane Library to identify relevant studies, including randomized controlled trials and retrospective studies. These studies report the application of computed tomography, positron emission tomography-computed tomography, magnetic resonance imaging, endobronchial ultrasound, and mediastinoscopy in the diagnosis of mediastinal lymph node staging of NSCLC. The quality of the literature was assessed using the Quality Assessment of Diagnostic Accuracy Study 2. The true positive, false positive, true negative, and false negative of each study was extracted. The corresponding sensitivity, specificity, and other indicators were calculated and the Summary Receiver Operating curve was established. Then, head-to-head and indirect comparison meta-analyses will be conducted. Results: The results of this study will be published in a peer-reviewed journal. Conclusion: This study will provide basis for mediastinal lymph node staging of non-small cell lung cancer. PROSPERO registration number: CRD42019145667
- Open Access
- 1 November 2019
- Published by Taylor & Francis in Patient Preference and Adherence
- Vol. ume 13, 1927-1939
Treatment Adherence And Persistence Among HIV-1 Patients Newly Starting Treatment
Objective: To assess adherence and persistence with first-line single-tablet regimen (STR) and multi-tablet regimen (MTR) antiretroviral therapy (ART) in newly treated HIV-1 patients. Methods: Retrospective analysis of longitudinal pharmacy claims among US patients initiating ART between 1/1/2016 and 5/31/2016 (index date was defined by first ART claim for STRs, and fill date for the last therapy in the regimen for MTRs). Adherence was assessed over a 12-month period and reported as the proportion of adherent or non-adherent (defined as ≤5-day and > a 5-day gap between successive fills, respectively) patients. Sensitivity analysis using ≤7-day and ≤14-day gap thresholds to define adherence was performed. Persistence was assessed as the number of days on therapy from index until treatment discontinuation (>90 day gap in therapy). Kaplan–Meier curves and Cox Proportional Hazard models were generated to evaluate discontinuation rates. Assessments were performed on STRs vs MTRs overall and by regimen. Results: Patients initiating ART (STR: n=10,623; MTR: n=2504) had a mean age of 42.8 years; 76.0% were male. STR patients were >2 times more likely to be adherent over 12 months than MTR patients (24.9% vs 11.7%, respectively). Patients using EVG/COBI/FTC/TAF had greater adherence than those using other STRs. Among MTRs, patients were more adherent with FTC/TDF+DTG (15.1%) than other MTRs. Persistence was also greater with STRs, with MTR patients being 61% more likely to discontinue therapy. Persistence was best for FTC/TAF-based regimens. Predictors of treatment discontinuation included younger age, female gender, and Medicare or Medicaid insurance type. Conclusion: Patients receiving STRs were significantly less likely to discontinue therapy and were more adherent with their regimens, providing further evidence of greater adherence and persistence with STRs versus MTRs. However, there was a large proportion of patients who interrupted or discontinued treatment. Further research examining treatment patterns beyond first line is warranted.
- 1 November 2019
- Published by Taylor & Francis in Patient Preference and Adherence
- Vol. ume 13, 1927-1939
Open AccessTreatment Adherence And Persistence Among HIV-1 Patients Newly Starting Treatment
Objective: To assess adherence and persistence with first-line single-tablet regimen (STR) and multi-tablet regimen (MTR) antiretroviral therapy (ART) in newly treated HIV-1 patients. Methods: Retrospective analysis of longitudinal pharmacy claims among US patients initiating ART between 1/1/2016 and 5/31/2016 (index date was defined by first ART claim for STRs, and fill date for the last therapy in the regimen for MTRs). Adherence was assessed over a 12-month period and reported as the proportion of adherent or non-adherent (defined as ≤5-day and > a 5-day gap between successive fills, respectively) patients. Sensitivity analysis using ≤7-day and ≤14-day gap thresholds to define adherence was performed. Persistence was assessed as the number of days on therapy from index until treatment discontinuation (>90 day gap in therapy). Kaplan–Meier curves and Cox Proportional Hazard models were generated to evaluate discontinuation rates. Assessments were performed on STRs vs MTRs overall and by regimen. Results: Patients initiating ART (STR: n=10,623; MTR: n=2504) had a mean age of 42.8 years; 76.0% were male. STR patients were >2 times more likely to be adherent over 12 months than MTR patients (24.9% vs 11.7%, respectively). Patients using EVG/COBI/FTC/TAF had greater adherence than those using other STRs. Among MTRs, patients were more adherent with FTC/TDF+DTG (15.1%) than other MTRs. Persistence was also greater with STRs, with MTR patients being 61% more likely to discontinue therapy. Persistence was best for FTC/TAF-based regimens. Predictors of treatment discontinuation included younger age, female gender, and Medicare or Medicaid insurance type. Conclusion: Patients receiving STRs were significantly less likely to discontinue therapy and were more adherent with their regimens, providing further evidence of greater adherence and persistence with STRs versus MTRs. However, there was a large proportion of patients who interrupted or discontinued treatment. Further research examining treatment patterns beyond first line is warranted.
- Open Access
- 1 May 2016
- Published by Elsevier in The Journal of Pediatrics
- Vol. 172, 127-135
Cost-Effectiveness/Cost-Benefit Analysis of Newborn Screening for Severe Combined Immune Deficiency in Washington State
- 1 May 2016
- Published by Elsevier in The Journal of Pediatrics
- Vol. 172, 127-135
Open AccessCost-Effectiveness/Cost-Benefit Analysis of Newborn Screening for Severe Combined Immune Deficiency in Washington State